MED1 and JAB1 in HER2-positive breast cancer progression and treatment resistance
Role of MED1 in HER2-mediated tumorigenesis
This work looks at how two proteins, MED1 and JAB1, influence growth, spread, and resistance to therapy in people with HER2-positive breast cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Cincinnati NIH-funded |
| Lab location | 1 site (Cincinnati, United States) |
| Project ID | NIH-11305236 on NIH RePORTER |
What this research studies
Researchers are using human tumor samples, genetic mouse models, and laboratory analyses to follow how MED1 and its partner JAB1 interact in HER2-driven breast cancers. They use RNA sequencing and molecular experiments to find which genes these proteins control and how that affects tumor growth and spread. The team has created MED1 mutant and overexpression mouse models and validated findings in human tissue arrays to link the biology to real tumors. The goal is to map the MED1–JAB1 pathway that may drive metastasis and resistance to current HER2 treatments.
Who could benefit from this research
Good fit: People with HER2-positive breast cancer, especially those with metastatic disease or tumors that are not responding well to current HER2 therapies, would be most relevant to this research.
Not a fit: Patients with HER2-negative breast cancer or those looking for immediate new treatments are unlikely to see direct benefit from this basic and preclinical work.
Why it matters
Potential benefit: If successful, this work could point to new targets or biomarkers to help treat or predict resistance in HER2-positive breast cancer patients.
How similar studies have performed: Prior laboratory and animal work has linked MED1 to HER2 and estrogen receptor signaling, but the specific MED1–JAB1 interaction as a driver of metastasis and resistance is a newer area still under testing.
Where this research is happening
Cincinnati, United States
- University of Cincinnati — Cincinnati, United States (Active)
Researchers
- Principal investigator: Zhang, Xiaoting — University of Cincinnati
- Study coordinator: Zhang, Xiaoting
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.